FDA and EMA Grant Orphan Designation to Xeris

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
FDA and EMA Grant Orphan Designation to Xeris Pharmaceuticals' Soluble Glucagon for Prevention of Hypoglycemia in Congenital Hyperinsulinism Patients

Austin, Texas, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. ("Xeris"),a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable drugs, announced today that the Food and Drug Administration has granted orphan drug designation for its soluble glucagon, an investigational new drug, for the prevention of severe, persistent hypoglycemia in patients with congenital hyperinsulinism (HI).  Additionally, upon a recommendation by the European Medicines Agency's Committee for Orphan Medicinal Products (EMA COMP), the European Commission (EC) has also granted Xeris' soluble glucagon orphan designation for HI.

Both FDA and EMA grant orphan designation to promote the development of therapies to treat rare diseases.  Incentives offered by FDA to companies to develop rare disease therapies include more frequent interaction with the FDA, tax credits related to development costs, waiver of prescription drug user fees for NDA submission, and a 7-year marketing exclusivity period in the U.S. following regulatory approval, and the potential for grant funding for clinical trial costs.

"We are pleased that both the FDA and EMA have recognized the importance of HI and designated orphan status for our soluble glucagon product for this indication." said Douglas R. Baum, Xeris' CEO.  "Covered by multiple US Investigational New Drug applications, we are developing several soluble glucagon products for patients with diabetes, we believe our glucagon can be useful in a number of other patient populations, such as the HI population, who suffer from severe, persistent hypoglycemia". 

Julie Raskin, the Executive Director of Congenital Hyperinsulinism International (CHI), the patient advocacy group for HI, offered that "CHI is very optimistic about the potential for Xeris' glucagon, particularly in the medical management of the diffuse form of HI which affects all the cells in the pancreas."  Historically, many patients with diffuse HI have had to undergo surgery to remove 95-98% of their pancreas to reduce insulin secretion to a level that does not result in repeated hypoglycemic episodes.  Raskin notes that "sadly, by 15 years of age, some 95% of these patients have insufficient insulin production and they become insulin-dependent for the remainder of their lives.  We are very supportive of new drug products that have the potential to reduce the enormous emotional and financial burden of HI on patients and their families.   Xeris soluble glucagon delivered via a pump is one of just a handful of new therapies to come along in 30 years."

About Congenital Hyperinsulinism

Congenital hyperinsulinism (HI) is the most frequent cause of severe, persistent hypoglycemia (very low blood sugar) in newborn babies and children. In most countries it occurs in approximately 1/25,000 to 1/50,000 births. About 60% of babies with HI develop hypoglycemia during the first month of life. An additional 30% will be diagnosed later in the first year and the remainder after that. Congenital hyperinsulinism is a condition that causes individuals to have abnormally high levels of insulin, which is a hormone that helps control blood sugar levels. Infants and children with HI have frequent and severe episodes of hypoglycemia. In infants and young children, these episodes are characterized by a lack of energy, irritability, or difficulty feeding. Repeated episodes of low blood sugar increase in HI patients result in permanent seizure disorder, learning disabilities, cerebral palsy, blindness or even death.  

About Glucagon

Glucagon is a metabolic hormone secreted by the pancreas that raises blood glucose levels by causing the liver to rapidly convert glycogen (the stored form of glucose) into glucose, which is then released into the bloodstream.  Glucagon and insulin are two critical hormones in a glycemic control system that keeps blood glucose at the right level in healthy individuals.  In patients with HI, genetic defects cause the pancreas to continuously overexpress insulin.  More commonly, glucagon is associated with people with diabetes who are dependent on insulin, where this control system is disrupted and insulin must be injected prior to meals to avoid high levels of blood glucose (hyperglycemia).  The opposite effect of low blood glucose (hypoglycemia) is also prevalent in this population, resulting from too much insulin or exercise. Severe If untreated, this leads to severe hypoglycemia, which is a serious condition and can cause seizures, coma, potential brain injury and, death.  Xeris proprietary glucagon formulation has the potential to provide the first soluble, room temperature stable, pump-delivered glucagon product for continuous infusion to combat high insulin levels and thus prevent severe hypoglycemia.

About Xeris Pharmaceuticals, Inc.

Xeris is an Austin, Texas-based, specialty biopharmaceutical company developing improved and differentiated injectable therapeutics for multiple indications including diabetes. The company's proprietary non-aqueous formulation technologies allow for the subcutaneous and intradermal delivery of highly concentrated, non-aqueous, ready-to-inject suspension and solution formulations of peptides, proteins, antibodies and small molecules.  Xeris' proprietary formulation approach intends to offer distinct advantages over existing products and formulations including:  up to 1000-fold lower injection volumes, eliminating the need for reconstitution and refrigeration, with extended room temperature shelf-life stability, all of which can lead to products that are easier to use by patients, caregivers, health practitioners, and that can reduce costs for payers and the healthcare system.  For more information, please visit the Xeris website at:  www.xerispharma.com

About Congenital Hyperinsulinism International

CHI is a leading nonprofit organization dedicated to improving the lives of children and adults living with congenital hyperinsulinism (HI).  CHI provides a world of information, resources, and support to the HI community.  CHI advocates on behalf of patients for better treatments and access to care.  CHI is dedicated to increasing awareness of the disorder, as it leads to more timely diagnosis and the best outcomes for patients.  CHI supports medical research for improved therapies, potential cures, and timely diagnosis.  CHI works globally because cooperation across borders fosters important advances in medicine. For more information, please visit the CHI website at:  www.congenitalhi.org  ;

Michelle Bybee Xeris Pharmaceuticals, Inc. (888) 570-4781x 707 www.xerispharma.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 101

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 160

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 56

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
Kendra Scott’s Dolly Tribute Tests Purposeful Luxury

Updated Category News Views 87

Butterflies, music notes, and a $70 pendant are carrying a surprisingly serious brand message this November. Kendra Scott’s new Dolly Parton Tribute Collection is plainly built to celebrate Dolly’s style, but it also shows how a consumer brand can make sentiment do some commercial heavy lifting without turning the whole thing into mush. The collection arrived November...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 61

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 0

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Premier Energy's €850M Debt Bet on Evryo Nears Close

Updated Category News Views 27

A Bridge Loan Gives Way to a Real Commitment Eight hundred and fifty million euros is not the sort of number a company tosses around for decoration. Premier Energy has secured a five-year senior facilities agreement to fund its planned acquisition of Evryo Group, including electricity distribution subsidiary Distribu?ie Energie Oltenia S.A., and to refinance roughly...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 106

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading

Top 5 Most Recently Viewed Articles

Latin Metals Gears Up for Drilling at Organullo Gold Project

Updated Category News Views 176

Latin Metals Achieves Drilling Milestone for Organullo Gold Project Latin Metals Inc. (TSXV: LMS) is excited to announce that it has successfully secured a crucial permit for exploration drilling at the Organullo Gold Project. This approval is a significant step forward in their commitment to mineral exploration in Argentina. What the Drill Permit Means for Latin Metals...

Continue Reading
TheSushiDragon Partners with StreamerDap to Empower Creators

Updated Category News Views 444

TheSushiDragon Joins StreamerDap as Co-Owner In a groundbreaking move for the live streaming community, TheSushiDragon, a prominent Twitch creator, has officially entered an equity partnership with StreamerDap, a leading platform revolutionizing the sponsorship landscape for creators. This innovative partnership aims to enhance the creator experience, making sponsorships...

Continue Reading
Tariffs, Inflation Insights: What Lies Ahead for Markets

Updated Category News Views 198

Market Trends: Understanding Recent Developments The market landscape has shown itself to be quite dynamic recently. As US President Donald Trump indicates the possibility of increased tariffs, there remains a juxtaposition of hope and uncertainty in the air. While discussions of a potential peace agreement between Russia and Ukraine seem to be gaining momentum, this has...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Bloom Energy Partners with Oracle to Boost AI Infrastructure

Updated Category News Views 301

Bloom Energy and Oracle: A Strategic Collaboration Bloom Energy Corp (NYSE: BE) is experiencing a notable surge in its stock prices following a recent announcement that highlights a significant partnership with Oracle Corp (NYSE: ORCL). This new collaboration aims to utilize Bloom's innovative fuel cell technology to deliver onsite power solutions for selected Oracle...

Continue Reading